LYNPARZA150mg

LYNPARZA (olaparib) 150mg tablets by AstraZeneca is the pioneering PARP inhibitor that revolutionized the treatment of BRCA-mutated cancers. As the first PARP inhibitor to receive FDA approval, LYNPARZA has established a new standard of care for patients with BRCA1/BRCA2 mutations across multiple cancer types. LYNPARZA exploits the concept of synthetic lethality—cancer cells with BRCA mutations already have defective DNA repair mechanisms. By inhibiting PARP (another DNA repair pathway), LYNPARZA creates a lethal accumulation of DNA damage specifically in cancer cells, leading to cell death while sparing normal cells. LYNPARZA is FDA-approved for maintenance treatment of BRCA-mutated advanced ovarian cancer, HER2-negative metastatic breast cancer with germline BRCA mutation, maintenance treatment of BRCA-mutated metastatic pancreatic cancer, and metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations. Clinical trials have demonstrated remarkable efficacy—the SOLO-1 trial showed LYNPARZA reduced the risk of disease progression or death by 70% in newly diagnosed advanced ovarian cancer with BRCA mutation. We provide authentic AstraZeneca LYNPARZA with worldwide delivery for oncology centers and distributors.